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Abstract
Background: In view of reported associations between high adiposity, particularly in midlife and late-life dementia
risk, we aimed to determine associations between body mass index (BMI), and BMI changes across adulthood and
brain structure and pathology at age 69–71 years.
Methods: Four hundred sixty-five dementia-free participants from Insight 46, a sub-study of the British 1946 birth
cohort, who had cross-sectional T1/FLAIR volumetric MRI, and florbetapir amyloid-PET imaging at age 69–71 years,
were included in analyses. We quantified white matter hyperintensity volume (WMHV) using T1 and FLAIR 3D-MRI;
β-amyloid (Aβ) positivity/negativity using a SUVR approach; and whole brain (WBV) and hippocampal volumes (HV)
using 3D T1-MRI. We investigated the influence of BMI, and BMI changes at and between 36, 43, 53, 60–64, 69 and
71 years, on late-life WMHV, Aβ-status, WBV and mean HV. Analyses were repeated using overweight and obese
status.
Results: At no time-point was BMI, change in BMI or overweight/obese status associated with WMHV or WBV at
age 69–71 years. Decreasing BMI in the 1–2 years before imaging was associated with an increased odds of being
β-amyloid positive (OR 1.45, 95% confidence interval 1.09, 1.92). There were associations between being overweight
and larger mean HV at ages 60–64 (β = 0.073 ml, 95% CI 0.009, 0.137), 69 (β = 0.076 ml, 95% CI 0.012, 0.140) and 71
years (β = 0.101 ml, 95% CI 0.037, 0.165). A similar, albeit weaker, trend was seen with obese status.
Conclusions: Using WMHV, β-amyloid status and brain volumes as indicators of brain health, we do not find
evidence to explain reported associations between midlife obesity and late-life dementia risk. Declining BMI in later
life may reflect preclinical Alzheimer’s disease.
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Background
Dementia affects 44 million people worldwide, with
prevalence predicted to triple by 2050. Vascular risk fac-
tors, including obesity, have been implicated as potential
targets for intervention to reduce dementia risk. How-
ever, it remains unclear how obesity might influence
subsequent brain health, and whether there are sensitive
age periods when risk exposure is particularly damaging.
Positive associations have been reported between obes-
ity and all-cause dementia [1, 2], but also with clinically-
diagnosed vascular [3, 4] and Alzheimer’s disease (AD)
dementia [5–7] with more consistent findings relating to
midlife, rather than late life, adiposity [8–10]. The patho-
physiological mechanisms mediating these relationships
are not well understood. Associations may be driven by
downstream consequences of obesity on other vascular
risk factors, namely hypertension, insulin resistance, and
dyslipidaemia [11], which have all been independently
implicated in dementia risk. Obesity also influences car-
diovascular health via endothelial dysfunction and pro-
inflammatory routes [12], which might also be impli-
cated in cerebral health.
We sought to determine the relationship between
body mass index (BMI), longitudinal BMI changes, and
obesity status across adulthood and cerebral small vessel
disease (SVD), brain volumes and fibrillar β-amyloid
pathology in early late life. We studied individuals from
a British birth cohort who have had BMI prospectively
and serially measured from their mid-30s onwards, and
cerebral imaging aged 69–71 years. We hypothesised
that (1) BMI would be most strongly associated with an
imaging marker of cerebral SVD and (2) there would be
specific periods when BMI and changes in BMI would
influence brain pathology.
Methods
Study design and participants
Participants were from Insight 46, a sub-study of the
MRC National Survey of Health and Development
(NSHD), a birth cohort which initially comprised 5362
individuals born throughout mainland Britain in 1 week
in 1946 [13]. Follow-up has included > 20 contacts since
birth, including home assessments by research nurses at
ages 36, 43, 53, and 69 years, and assessment at a clinical
research facility at age 60–64 years. Participants were eli-
gible for inclusion in the Insight 46 sub-study if this de-
fined set of life course data were available, and where
willingness to attend a clinic visit in London had previ-
ously been expressed. Individuals with contraindications
to MRI or PET (including claustrophobia and metallic
implants) were excluded. Further eligibility criteria have
been described elsewhere [14]. Between 2015 and 2018,
502 participants were assessed at University College
London [14], when aged 69–71 years. An overview of
recruitment is provided in Figure e-1 (supplementary).
Comparisons between Insight 46 participants and the
larger NSHD have previously been reported [15].
Procedures
Imaging was performed on a single Biograph mMR 3 T
PET/MRI scanner (Siemens Healthcare, Erlangen), with
simultaneous acquisition of dynamic PET/MR data,
including volumetric (1.1 mm isotropic) T1 and T2-
weighted Fluid Attenuated Inversion Recovery (FLAIR)
sequences [14]. β-amyloid burden was assessed using
[16] F florbetapir (Amyvid). PET data were processed
using an automated in-house processing pipeline includ-
ing pseudo-CT attenuation correction [14]. Global
standardised uptake value ratio (SUVR) was calculated
from cortical regions of interest (ROIs) comprising the
lateral and medial frontal, anterior and posterior cingu-
late, lateral parietal, and lateral temporal regions, nor-
malised to eroded subcortical white matter. Positive/
negative β-amyloid status was determined using a
Gaussian mixture model applied to SUVR values, taking
the 99th percentile of the lower (β-amyloid negative)
Gaussian as the cut-point (0.61).
Volumetric T1-weighted and FLAIR images underwent
visual quality control (QC), before processing using vali-
dated automated pipelines: [14] whole-brain volume
(WBV) segmentation using MAPS [17], hippocampal
volumes (HV) using STEPS [18], with appropriate man-
ual editing; and total intracranial volume (TIV) using
SPM12 [16]. A validated, unsupervised automated algo-
rithm, BaMoS (Bayesian Model Selection) [19] was used
to segment white matter hyperintensities (WMH) from
T1/FLAIR images, followed by visual QC and manual
editing where appropriate, generating a global WMH
volume (WMHV) including subcortical grey matter but
excluding infratentorial regions.
Participants were classified as cognitively normal,
having mild cognitive impairment (according to re-
search criteria [20]) or dementia, based on expert
consensus, informed by clinical history, informant his-
tory, MMSE [21], and cognitive performance (WMS-R
Logical Memory test [22] and WAIS-R Digit symbol
substitution test [23]).
BMI and other covariates
Height and weight measurements were collected by
standard protocol as part of NSHD assessments at ages
36, 43, 53, 60–64, and 69 years, and at the Insight 46 as-
sessment at age 69–71 years (which for clarity will subse-
quently be referred to as 71 years). BMI was defined as
the weight in kilogrammes divided by the square of the
height (in metres). Abdominal circumference (AC), was
measured to the nearest mm using a standardised proto-
col at 36, 43, 53, 60–64 and 69 years.
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Using an approach previously employed in the NSHD,
BMI change for the periods 36–43, 43–53, 53–60/64,
60/64–69 and 69–71 years, conditional on earlier mea-
surements, was calculated as the residual from the re-
gression of each BMI measure (from 43 years) on the
earlier measure(s) for each sex, using individuals with
available data at all time-points. Residuals represent a
change in BMI above/below that expected on average
given the earlier BMI. Residuals were standardised,
allowing comparison between periods [24]. AC change
variables were derived using the same approach.
Vascular risk factors selected for adjustment in statis-
tical models included systolic blood pressure (SBP) con-
temporaneous with BMI measurement, and smoking
status, hypercholesterolaemia, and diabetes mellitus
(DM) status at the time of the Insight 46 assessment.
Seated BP was measured in the upper arm twice after 5
min’ rest at ages 36, 43, 53, 60–64 and 69, and a lying
BP collected after 3 min rest at age 71 years. The second
BP measure was used for analyses, unless missing.
Smoking status was defined by questionnaire (at age 68
years, or if missing at 60–64 years) as never-smoked, ex-
smoker and current smoker. Hypercholesterolaemia
status was based on self-reported use of cholesterol-
lowering medication at Insight 46 assessment or random
total cholesterol ≥ 5mmol/L at 69 years. Diabetes melli-
tus (DM) status was based on self-reported diabetic
medication use at Insight 46 assessment, HbA1c > 6.5%
or a self-reported diagnosis at 69 years. APOE genotyp-
ing was performed using standard techniques and indi-
viduals categorised as APOE-ε4 carriers or non-carriers.
Adult socioeconomic position (SEP) was defined as non-
manual or manual, based on the occupation at 53 years
according to the UK Registrar General’s Classification of
Occupations.
A measure of affective symptoms was available at age
69 years derived from the general health questionnaire
(GHQ-28 [25]), with a score of > 5 defined as probable
anxiety or depression.
Statistical analysis
Analyses were performed in Stata v.14.1 (Stata Corp).
Participants were included if they were dementia-free,
and had acceptable quality amyloid PET/MR imaging.
For WMH and brain volume analyses, individuals with
cortical infarcts inappropriately segmented as WMH
(n = 5), atypical vascular pathology (n = 1) or white mat-
ter pathologies not considered to be of vascular origin
e.g. demyelination (n = 3) were excluded. For brain vol-
ume analysis individuals also needed a useable amyloid
scan, since the amyloid status was included as a covari-
ate in the fully-adjusted model. Otherwise, all individ-
uals, including those with neurological diagnoses, with
available BMI/AC data at any time-point, were included
for generalisability.
BMI and AC at each visit (up to age 69 years, which
was the last time-point that an assessment was per-
formed across the entire cohort) were compared be-
tween Insight 46 participants and the larger NSHD,
using unadjusted linear mixed effect models for men
and women separately, using all available measurements.
An unstructured residual variance-covariance matrix
was used to model the correlation between repeated
measures in an individual.
Due to the non-normal distribution of WMHV, gener-
alised linear models (GLM) using the gamma distribu-
tion with log link were used to investigate relationships
between BMI at each age separately and WMHV at 71
years. Linear regression was used to investigate relation-
ships between BMI at each age and WBV and mean HV
at 71 years. Model 1 adjusted for sex, TIV and scanning
age. Model 2 also adjusted for SBP contemporaneous
with BMI measurement. Model 3 additionally adjusted
for other potential cardiovascular confounders: smoking
status, diabetic status, hypercholesterolaemia status at
the time of Insight 46 assessment, and adult SEP. For
brain volume analyses, to explore BMI influences inde-
pendently of measurable brain pathologies, model 3 also
adjusted for global WMHV and β-amyloid status.
BMI change variables were then treated as the main pre-
dictor within GLM/linear regression models: Model 1(c):
all BMI conditional change variables included and ad-
justed for sex, TIV and scanning age. Model 2(c): each
conditional change variable assessed individually and ad-
justed for contemporaneous SBP (e.g. in the model exam-
ining BMI change between 36 and 43 years, SBP at 43
years was included in the model) and the covariates de-
scribed in model 3 above. These models address whether,
regardless of previous weight gain, there is a period when
weight change has a particularly strong association with
an imaging outcome measure at age 71 years.
We used logistic regression to test associations be-
tween BMI at ages 36 through to 71 years and β-amyloid
status (positive or negative). Model 1 adjusted for sex.
Model 2 further adjusted for APOE-ε4 status. Model 3
also adjusted for contemporaneous SBP. Additional vas-
cular risk factors were not included in models due to the
limited number of β-amyloid-positive individuals. Asso-
ciations between BMI change and β-amyloid status were
investigated using two models: Model 1(c) included all
conditional change variables within the same model,
adjusting for sex. Model 2(c) assessed each conditional
change variable individually and adjusted for contempor-
aneous SBP and APOE-ε4 status. A differential influence
of BMI (or change) on β-amyloid status by APOE-ε4 sta-
tus was tested using an interaction term in fully-adjusted
models.
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In an exploratory analysis, all continuous BMI and
BMI change models were repeated replacing BMI with
AC, to determine whether a measure of central adiposity
might be more strongly associated with imaging
measures.
Model assumptions were checked with regression
diagnostics, including checks of linearity by examination
of residuals. Possible non-linear relationships were ex-
plored through the creation of a categorical variable de-
fining individuals as normal weight (BMI < 25 kg/m2),
overweight (25 < BMI < 30 kg/m2) or obese (BMI > 30
kg/m2) which was then used in models 1–3, replacing
BMI as the independent variable. Too few individuals
were underweight (BMI < 18.5 kg/m2) at any given age to
create a separate category and were therefore treated as
normal weight. Sensitivity analyses were performed ex-
cluding these individuals. Interactions between BMI and
sex at each time point were investigated with appropri-
ate interaction terms.
To explore the potential influence of cumulative adi-
posity on imaging measures, individuals were categorised
by obese status at each time point and then a cumulative
score calculated using the sum of the number of time-
points that an individual was classed as obese. This vari-
able was used as the predictor of interest in fully-
adjusted models for each imaging outcome. Individuals
missing any BMI measures were excluded from this
analysis.
Standard protocol approvals, registrations, and patient
consents
Ethical approvals for the wider NSHD have been de-
scribed [26]. Insight 46 was approved by the Queen
Square Research Ethics Committee. All participants pro-
vided written informed consent.
Data availability policy
A data-sharing policy is in place: anonymised data will
be shared by request from any qualified investigator
(https://skylark.ucl.ac.uk/NSHD/doku.php).
Results
Of the 502 individuals assessed as part of Insight 46, 471
(93.4%) completed the imaging protocol. 468 (93.2%) of
Insight 46 individuals were dementia-free. Following im-
aging processing and QC, 457 (91.0%) scans were avail-
able for amyloid analysis, 445 (88.6%) for brain volume
analysis and 453 (90.2%) for WMHV analysis. Partici-
pant characteristics of those with available imaging are
summarised in Table 1. Table e-1 (supplementary) sum-
marises participant characteristics between individuals
with complete BMI data, individuals missing BMI data
at any time-point and individuals who did not complete
the scanning protocol. Compared with individuals who
completed scanning, participants who did not complete
scanning tended to have a higher BMI (age 71 years:
mean BMI (SD) 27.4 (4.2) kg/m2 in scanned individuals
versus 30.4 (5.7) kg/m2 in individuals not scanned).
Mean age at scanning was 70.7; SD 0.7 years. 18.2%
were β-amyloid positive. Prevalence of obesity increased
from 3.1% at age 36 years to 26.5% at age 71 years. Fig-
ure 1 shows the pattern of BMI and AC trajectories in
Insight 46 individuals (n = 502) compared with the larger
NSHD (BMI: n = 3188; AC: n = 3193). Female partici-
pants in Insight 46 had a predicted BMI 0.8 kg/m2 (p =
0.03) and AC 2.5 cm smaller (p = 0.01) than those in the
main cohort at any given time-point. Differences in
males were smaller, with those in Insight 46 having a
predicted BMI 0.3 kg/m2 (p = 0.2) less and AC 1.2 cm
(p = 0.2) smaller than those in the main cohort.
BMI, BMI change and weight status at all time-points
investigated were not associated with WBV or WMHV
at age 71 years (Tables 2, 3 and 4).
At age 53 years, being overweight, compared with nor-
mal weight, was associated with a significantly lower risk
of being β-amyloid positive at age 71 years (OR 0.51, p =
0.026, model 3). An association in the same direction, al-
though substantially weaker, was seen with obese status
(OR 0.89, p = 0.77, model 3). This pattern persisted at
subsequent time-points, albeit associations were weaker
(p > 0.08, all tests). In late life, there was a trend that
higher BMI (ages 71 years: OR 0.95, p = 0.08, model 3),
was associated with a decreased likelihood of being β-
amyloid positive (Table 2). Consistent with this, greater
increases in BMI between the home visit at age 69 years
and Insight 46 assessment at age 71 years were associ-
ated with a significantly decreased likelihood of being β-
amyloid positive (Table 4). Alternatively, a 1 SD decrease
in BMI was associated with an increased likelihood of
being β-amyloid positive (OR 1.45, 95% CI 1.09, 1.92).
Further adjustment for time between assessments (mean
1.2; SD 0.6 years), presence of significant affective symp-
toms and exclusion of individuals with MCI did not alter
the association (data not shown). There was no evidence
of an interaction with APOE-ε4 carrier status in any ana-
lyses (all interaction p values > 0.23).
Being obese at age 36 years was associated with 0.167
ml larger mean HV at age 71 years, although it should
be noted that this was a small group (n = 13) and confi-
dence intervals were wide. Subsequently, from age 60–
64 years onwards, being overweight (p < 0.026, all tests,
model 3), and to a lesser extent, obese (p < 0.28, all tests,
model 3), was associated with larger HV compared with
being normal weight (Table 3). The association at age
36 years was attenuated when adjusting for WBV (p =
0.12), but all other associations remained largely un-
changed. Exclusion of individuals with MCI did not sub-
stantially alter associations observed from age 60–64
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Table 1 Characteristics of dementia-free participants having at least one outcome of interest
Variable N men/women (total) Value in men and
women combined
Age at assessment, mean (SD) 238/227 (465) 70.7 (0.7)
Age at scanning, mean (SD) 238/227 (465) 70.7 (0.7)
β-Amyloid positive, n (%) 232/225 (457) 83 (18.2)
Whole brain volume in ml, mean (SD) 227/218 (445) 1100.0 (98.4)
Mean hippocampal volume in ml, mean (SD) 227/218 (445) 3.1 (0.3)
White matter hyperintensity volume in ml, median (IQR) 233/220 (453) 3.1 (1.6, 6.8)
Total intracranial volume in ml, mean (SD) 233/220 (453) 1434.0 (132.3)
MMSE/30, mean (SD) 238/227 (465) 29.3 (0.9)
BMI at 36 years in kg/m2, mean (SD) 217/209 (426) 23.7 (3.1)
BMI at 43 years in kg/m2, mean (SD) 231/215 (446) 24.9 (3.2)
BMI at 53 years in kg/m2, mean (SD) 232/224 (456) 26.9 (4.1)
BMI at 60–64 years in kg/m2, mean (SD) 238/227 (465) 27.5 (4.1)
BMI at 69 years in kg/m2, mean (SD) 236/222 (458) 27.6 (4.4)
BMI at 71 years in kg/m2, mean (SD) 238/227 (465) 27.6 (4.4)
AC at 36 years in cm, mean (SD) 217/209 (426) 81.7 (11.0)
AC at 43 years in cm, mean (SD) 230/218 (448) 83.0 (11.2)
AC at 53 years in cm, mean (SD) 232/225 (457) 90.4 (12.0)
AC at 60–64 years in cm, mean (SD) 238/227 (465) 95.5 (11.7)
AC at 69 years in cm, mean (SD) 236/223 (459) 95.1 (12.3)
Weight category at age 36, n (%) Underweight 217/209 (426) 9 (2.1)
Normal weight 303 (71.1)
Overweight 101 (23.7)
Obese 13 (3.1)
Weight category at age 43, n (%) Underweight 231/215 (446) 3 (0.7)
Normal weight 245 (54.9)
Overweight 168 (37.7)
Obese 30 (6.7)
Weight category at age 53, n (%) Underweight 232/224 (456) 0 (0)
Normal weight 155 (34.0)
Overweight 220 (48.3)
Obese 81 (17.8)
Weight category at age 60–64, n (%) Underweight 238/227 (465) 0 (0)
Normal weight 143 (30.8)
Overweight 201 (43.2)
Obese 121 (26.0)
Weight category at age 69, n (%) Underweight 236/222 (458) 2 (0.4)
Normal weight 142 (31.0)
Overweight 195 (42.6)
Obese 119 (26.0)
Weight category at age 71, n (%) Underweight 238/227 (465) 2 (0.4)
Normal weight 145 (31.2)
Overweight 195 (41.9)
Obese 123 (26.5)
Lane et al. Alzheimer's Research & Therapy           (2021) 13:91 Page 5 of 19
Table 1 Characteristics of dementia-free participants having at least one outcome of interest (Continued)
Variable N men/women (total) Value in men and
women combined
Smoking status at age 68, n (%) Current smoker 238/227 (465) 16 (3.4)
Ex-smoker 286 (61.5)
Never smoked 163 (35.1)
Hypercholesterolaemia at age 71, n (%) 238/227 (465) 369 (79.4)
Diabetes mellitus at age 71, n (%) 237/224 (461) 50 (10.9)
SBP at age 71 in mmHg, mean (SD) 237/227 (464) 137.0 (16.9)
Adult socioeconomic position, n (%) Non-manual (Class I-IIIN) 238/2427 (465) 395 (84.9)
Manual (Class IIIM-V) 70 (15.1)
APOE-ε4 carrier (1 or 2 alleles), n (%) 230/225 (455) 131 (28.8)
BMI body mass index, IQR interquartile range, MMSE mini-mental state examination, n number, SBP systolic blood pressure, SD standard deviation
Fig. 1 BMI and AC across adulthood in Insight 46 participants and the larger NSHD Line graphs comparing predicted BMI (top panels) and AC
(bottom panels) in males (a, c) and females (b, d) between Insight 46 participants and individuals with available measures in the larger NSHD
from ages 36 up to 69 years (the last age the whole NSHD cohort were assessed). 95% confidence intervals shown. Predictions are marginal
means at each time-point from a linear mixed effects model fitted jointly across BMI or AC measures at all time-points. AC, abdominal
circumference; BMI, body mass index
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years onwards (data not shown). BMI changes were not
associated with mean HV (Table 4).
In single time-point (continuous and categorical) and
change analyses, there was no clear evidence of sex in-
teractions for WMHV, WBV or amyloid analyses (all sex
interactions p > 0.05). In hippocampal analyses, there
was a suggestion of a sex interaction in continuous BMI
analyses at age 69 (p = 0.038) with a similar, albeit
borderline, interaction at age 71 years (p = 0.055), sug-
gesting that higher BMI was associated with larger HV
in women, but not men (age 69: women: coefficient
0.009 ml per kg/m2, 95% CI 0.001, 0.016, p = 0.027; men:
− 0.005 ml per kg/m2, 95% CI -0.015, 0.005, p = 0.36; age
71: women: 0.009 ml per kg/m2, 95% CI 0.001, 0.017,
p = 0.028; men: − 0.003 ml per kg/m2, 95% CI -0.013,
0.006, p = 0.50); there was however no evidence of a
similar interaction in the categorical analyses (all inter-
action p values > 0.09).
Removing underweight individuals did not alter cat-
egorical weight analysis results.
There were no associations between AC and AC
change at any age and WMHV, amyloid status or mean
HV. Coefficients did not substantially alter between
models and therefore results for model 3 only are pre-
sented (Tables 5 and 6). There was no association
between AC at any time point and WBV, but increasing
AC between 60–64 and 69 years was associated with
smaller WBV (model 3: p = 0.010, Table 6). In the amyl-
oid analyses, there was no evidence of an APOE-ε4 inter-
action (all interaction p values > 0.20). There was no
evidence of sex interactions in AC analyses (all inter-
action p values > 0.08).
There was no evidence that duration of obesity was
associated with imaging outcome measures (WMHV
exponentiated coefficient 0.98, 95% CI 0.92, 1.05; ad-
justed β-amyloid odds ratio 0.96, 95% CI 0.81, 1.13;
WBV β coefficient 0.3, 95% CI − 2.5, 3.0; mean HV β co-
efficient 0.008, 95% CI − 0.009, 0.026).
With respect to included vascular covariates in
fully-adjusted models, using the continuous BMI
analysis at age 71 years as a representative model:
contemporaneous SBP was associated with larger
WMHV (exponentiated coefficient 1.01, 95% CI 1.002,
1.01, p = 0.007), being diabetic was associated with
smaller WBV (β coefficient − 18.8, 95% CI − 32.2, −
5.3, p = 0.006) and ex-smokers had significantly
smaller HV compared with non-smokers (β coefficient
− 0.07, 95% CI − 0.12, − 0.009, p = 0.024). Cholesterol
status was not associated with any imaging measure
(p > 0.61, all models).








Mean HV β coefficient
(95% CI)
Model 3 Model 3 Model 3 Model 3
36 years
WMHV: Model 3: n = 409
Amyloid: Model 3: n = 412
WBV/HV: Model 3: n = 401
0.91 (0.81, 1.02) 1.08 (0.80, 1.47) 4.0 (−1.0, 9.1) 0.018 (− 0.014, 0.051)
43 years
WMHV: Model 3: n = 425
Amyloid: Model 3: n = 431
WBV/HV: Model 3: n = 417
0.95 (0.84, 1.06) 0.91 (0.66, 1.25) 2.5 (− 2.7, 7.7) 0.011 (− 0.022, 0.044)
53 years
WMHV: Model 3: n = 437
Amyloid: Model 3: n = 442
WBV/HV: Model 3: n = 429
0.93 (0.84, 1.03) 0.88 (0.67, 1.15) 1.5 (− 2.8, 5.9) 0.003 (− 0.026, 0.032)
60/64 years
WMHV: Model 3: n = 448
Amyloid: Model 3: n = 454
WBV/HV: Model 3: n = 440
0.95 (0.87, 1.05) 0.80 (0.62, 1.03) 0.0 (− 4.0, 4.0) 0.007 (− 0.019, 0.033)
69 years
WMHV: Model 3: n = 447
Amyloid: Model 3: n = 449
WBV/HV: Model 3: n = 439
0.97 (0.88, 1.06) 0.83 (0.65, 1.05) − 1.8 (− 5.5, 2.0) 0.004 (− 0.020, 0.029)
All coefficients or ORs quoted are per 10 cm increase in AC. Associations with WMHV were investigated using GLM, amyloid status using logistic regression and
brain volumes using linear regression models. 95% confidence intervals are also shown. Associations significant at p < 0.05 are highlighted in bold. Model
numbers are stated in the left-hand column. Results are similar across models and therefore only results for fully-adjusted model 3 are presented. Model 3
analyses adjust for sex, TIV, scanning age, contemporaneous SBP, DM, hypercholesterolaemia, adult SEP, smoking (WMHV models) and also β-amyloid status and
global WMHV (brain volume analyses). β-amyloid model 3 analyses adjust for sex, contemporaneous SBP and APOE-ε4 status. AC abdominal circumference, CI
confidence interval, DM diabetes mellitus, GLM generalised linear model, SBP systolic blood pressure, SEP socioeconomic position, TIV total intracranial volume,
WMHV white matter hyperintensity volume
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Discussion
In this population-based cohort, all of very similar age at
the time of assessments, we did not observe an associ-
ation between higher or increasing adiposity, as mea-
sured using BMI, or overweight/obese status, during
early adulthood, midlife and early late life, and WMHV
(a marker of cerebral SVD) or whole brain volume at
age 71 years. Conversely, higher BMI from midlife was
associated with decreased likelihood of being β-amyloid
positive, and having larger mean hippocampal volume.
Declining BMI in the year prior to scanning was particu-
larly associated with increased likelihood of β-amyloid
positivity. There was no evidence that cumulative expos-
ure to obesity was associated with brain structure and
pathology in early late life. Additional post hoc analysis
identified no significant association between cognitive
function (PACC) at age 69 and BMI at ages 60, 69 or 71.
Possible mechanisms by which obesity has been sug-
gested to influence cerebrovascular disease include via
its relationship with other vascular risk factors such as
hypertension, insulin resistance and hyperlipidaemia
[11]. However, adjustment for vascular risk factors can-
not explain the lack of association in our analysis be-
cause we did not see an association between increased
adiposity (using both BMI and also AC: a measure of
central adiposity, thought to be a better marker of more
metabolically active visceral fat) and higher burdens of
WMH in either adjusted or unadjusted analyses. Previ-
ous population-based studies investigating the
relationship between elevated adiposity and cerebral
SVD have not, in general, reported significant associa-
tions. Neither the AGES-Reykjavic study [27], Framing-
ham cohort [28] nor the ARIC study [29] found an
association between adiposity in midlife and subsequent
WMHV. A further cross-sectional study in the Framing-
ham cohort failed to find an association between WMH
and obesity using visceral and subcutaneous fat mea-
sured by CT [30]. In contrast, the CAIDE study reported
an association between both midlife and late-life obesity
and late-life WMH, even accounting for other vascular
risk factors. The risk however was mitigated in those
who lost weight by late life [31], which may suggest the
midlife association was driven by the tendency for BMI
to track over time, and risk accumulation may be crit-
ical. We however did not find evidence to support this
theory.
Overweight, but not obese, individuals, at age 53 were
less likely to be β-amyloid positive at age 71 years, but
there was no relationship between midlife continuous
measures of adiposity (BMI/AC) and subsequent β-
amyloid status, and therefore this finding should be
treated with caution. Being obese in midlife was not ad-
versely associated with β-amyloid status at age 71 years,
which is in contrast to findings reported by the ARIC
study [32]. This might be a consequence of the older
population investigated in ARIC, and a higher preva-
lence of obesity in midlife (25.8%), compared with 17.8%
in the 1946 cohort at age 53 years. The Mayo Clinic







Mean HV β coefficient
(95% CI)
Model 2(c) Model 2(c) Model 2(c) Model 2(c)
36–43 years
WMHV: Model 2: n = 390
Amyloid: Model 2: n = 391
WBV/HV: Model 2: n = 382
0.98 (0.89, 1.09) 0.95 (0.72, 1.26) 1.4 (− 3.2, 5.9) 0.006 (− 0.023, 0.035)
43–53 years
WMHV: Model 2: n = 391
Amyloid: Model 2: n = 391
WBV/HV: Model 2: n = 383
0.96 (0.86, 1.08) 0.89 (0.67, 1.17) −1.4 (− 6.0, 3.3) − 0.013 (− 0.042, 0.017)
53–60/64 years
WMHV: Model 2: n = 394
Amyloid: Model 2: n = 395
WBV/HV: Model 2: n = 386
1.01 (0.90, 1.13) 0.84 (0.63, 1.10) − 1.7 (− 6.3, 2.9) 0.007 (− 0.022, 0.036)
60/64–69 years
WMHV: Model 2: n = 395
Amyloid: Model 2: n = 396
WBV/HV: Model 2: n = 387
1.00 (0.89, 1.12) 0.95 (0.73, 1.25) − 6.0 (− 10.5, − 1.5) − 0.013 (− 0.042, 0.016)
WMHV coefficients represent the relative change in mean WMHV per 1 SD increase in the expected AC change across each time-interval using GLM. Adjusted
amyloid ORs are quoted per 1 SD increase in the expected BMI change from logistic regression models. Brain volume β coefficients represent the change in brain
volume (ml) per 1 SD increase in the expected AC change from linear regression models. Associations significant at p < 0.05 are highlighted in bold. Results are
similar across models and therefore only results for fully-adjusted model 2(c) are presented. Model 2(c) analyses examine each change variable separately and
adjust for sex, TIV, scanning age, contemporaneous SBP, DM, hypercholesterolaemia, adult SEP, smoking (WMHV models) and β-amyloid status and global WMHV
(brain volume analyses). β-amyloid model 2(c) analyses examine each change variable separately and adjust for sex, contemporaneous SBP and APOE-ε4 status.
AC abdominal circumference, CI confidence interval, DM diabetes mellitus, GLM generalised linear model, HV hippocampal volume, OR odds ratio, SBP systolic
blood pressure, SD standard deviation, SEP socioeconomic position, TIV total intracranial volume, WBV whole brain volume, WMHV white matter
hyperintensity volume
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Study of Aging however failed to observe an association
between midlife obesity and later-life β-amyloid status,
despite having a higher proportion of midlife obesity
(33%) [33].
In early late life (ages 69 and 71 years), there was a
trend towards lower BMI being associated with a greater
likelihood of being β-amyloid positive; in keeping with
this, those individuals who had a decelerating/declining
BMI trajectory in the 1–2 years prior to imaging were
more likely to be β-amyloid positive. It is well reported
that BMI declines in the years prior to clinically manifest
dementia, both all-cause, and clinically diagnosed AD
dementia [34, 35], the so-called obesity paradox, thought
to reflect reverse causality [8–10]. In preclinical AD, an
inverse relationship between BMI and β-amyloid burden
has been reported in ADNI subjects, although they did
not observe a change in BMI longitudinally between β-
amyloid positive and negative individuals [36]. Our ap-
proach, which assesses how an individual’s trajectory has
changed compared with what would be expected based
on the previous trajectory, is likely to be more sensitive
to early changes in slope rather than assessing absolute
value change. The Harvard Aging Brain study also
reported an inverse relationship between BMI and β-
amyloid burden, but, unlike in our study, only in APOE-
ε4 allele carriers [37].
Possible mechanisms linking changes in body compos-
ition with AD pathology include β-amyloid adversely
influencing hypothalamic satiety mechanisms. Cortico-
limbic structures are involved in modulating hypothal-
amic control of food intake, including the orbitofrontal
cortex and the cingulate cortex [38], both areas affected
by early β-amyloid deposition [39]. β-amyloid pathology
within the hypothalamus may also disrupt leptin (an
appetite-regulating adipokine)-mediated metabolic con-
trol [40]. Neuropsychiatric changes such as depression
may precede cognitive symptoms in the preclinical phase
[41] influencing dietary behaviour, although including a
measure of affective symptoms in the analysis did not in-
fluence the relationship, arguing against this possibility.
Alternatively, physical frailty, a phenomenon in older
age which includes reduced gait speed and reduction in
BMI, and β-amyloid accumulation, may share a common
underlying pathophysiological mechanism, such as in-
flammation [42].
We found no associations between BMI, BMI change
or overweight/obese status across adulthood and later-
life whole brain volume. However, increasing central
adiposity, from age 60/64 to 69 years was associated with
smaller WBV, although this did not reach significance in
the single time-point analyses. The lack of a similar
finding in BMI work may be because central adiposity is
a better marker of visceral adiposity, which is more
metabolically active than subcutaneous fat. Obesity is
associated with increased production of pro-
inflammatory cytokines, such as IL-6 and TNFα, which
are associated with cognitive decline [43]. However, a
similar association was not observed when examining re-
lationships with mean hippocampal volume meaning this
finding should be treated with caution.
However, from late midlife, being overweight, and lat-
terly, obese, was positively associated with mean hippo-
campal volume at age 71 years, with a similar trend in
the continuous BMI analyses, even accounting for head
size. These associations were independent of β-amyloid
pathology and WMHV, and a sensitivity analysis which
excluded individuals with MCI did not reduce this asso-
ciation. Furthermore, reverse causality is unlikely to en-
tirely account for the association since it extended back
~ 8 years prior to scanning in a dementia-free cohort.
Interestingly, this is consistent with a previous finding
from the NSHD that individuals with weight gain at age
53 years had better memory function at that age [44]. It
is possible that the association, to a degree, represents a
selective protective effect of increased adiposity on hip-
pocampal volume, which would explain the discrepancy
with WBV findings. Leptin, produced by adipose tissue,
has been shown to have an acute neurotrophic and neu-
roprotective effect on the hippocampus [45]. However,
although circulating leptin levels are higher in obesity,
CSF levels have been shown to be reduced, suggestive of
a central resistance [46], and would argue against this
hypothesis, and a similar relationship was not observed
in the central adiposity analyses. This observation re-
quires further investigation in longitudinal imaging
work.
Several large population-based studies have investi-
gated the relationship between midlife adiposity and
brain volume with inconsistent findings. The Framing-
ham Offspring Cohort found an inverse cross-sectional
relationship between measures of adiposity, particularly
visceral fat, and total brain volume in midlife, and larger
temporal horn volume (THV) (a proxy marker of hippo-
campal volume) with greater waist:hip ratio (WHR), ac-
counting for vascular risk factors. Longitudinally they
found an inverse relationship between midlife WHR, but
not BMI, and longitudinal global brain loss but no rela-
tionship with THV [28]. More recently, the AGES-
Reykjavik study found no association between midlife
higher adiposity and late-life total brain volume [27].
Cross-sectional studies in late life have also reported a
negative relationship between higher BMI and global
brain volume [47]. None to our knowledge has reported
positive associations between BMI and brain volumes.
Our findings might reflect a survival bias in this study,
whereby overweight/obese individuals who were suscep-
tible to the negative impact of obesity on neuronal
health have been lost to follow up.
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A relationship between obesity, particularly in midlife
and late-life dementia risk, has been reported across sev-
eral population studies, although this is not consistently
the case [8]. A large population-based study in the UK
reported an inverse association between midlife obesity
and late-life dementia risk, and a corresponding positive
association with midlife underweight status [48], which
is more consistent with our findings. There is limited lit-
erature on adiposity trajectories and their association
with dementia risk. The Honolulu-Asia Aging study
(HAAS) failed to find a relationship between BMI trajec-
tories in men and late-life all-cause dementia, but
greater BMI increases were seen in individuals who de-
veloped clinically-diagnosed vascular dementia, even ac-
counting for other vascular risk factors [49]. In contrast,
a study in Swedish women found slower BMI increases
from 38 to 70 years in those who went on to develop de-
mentia [50]. Discrepancies between studies may arise
due to population differences (including sex, age at base-
line and study duration) and methodological differences
(including approaches to measuring adiposity and num-
ber/timing of measurements collected).
This study has several strengths, including the multiple
time-points at which adiposity metrics have been mea-
sured, the very similar age of participants, who are
broadly representative of people born in mainland Brit-
ain in 1946, and use of a single scanner.
Limitations
Limitations include the possibility of survival bias, and
loss of individuals with pre-existent significant cognitive
symptoms, which may mask possible associations be-
tween obesity and cerebral pathology. There are limita-
tions inherent to any birth cohort. Whilst participants
are broadly representative of the population born in
mainland Britain in 1946, Insight 46 is a cohort consist-
ing of exclusively white British participants, which might
reduce generalisability to non-white populations. More-
over, having all been born in the same week, participants
went through childhood, adolescence and midlife at the
same time and are likely to have been exposed to the
similar environmental and societal factors, and prior to
current guidance and advice regarding weight, diet, and
exercise. These factors are likely to differ from those of
individuals born at other times. Individuals in Insight 46
tended to have lower BMI and AC than those in the lar-
ger NSHD cohort, although absolute differences were
small. We have previously demonstrated that Insight 46
participants are healthier with lower rates of overweight/
obesity at age 69 years than in the larger NSHD cohort,
and, consistent with these findings, obese individuals
were less likely to tolerate scanning [15] reducing the
ability to detect true associations. Rates of dementia at
this age are very low – 3/471 individuals in this study
were diagnosed with dementia and excluded (Figure e1),
and we do not think these are likely to have affected our
results. There are few underweight individuals, limiting
the power to detect potential U-shaped relationships be-
tween adiposity and late life cerebral pathology. Obesity
may have a detrimental impact on other markers, such
as lacunes (noting their relatively low prevalence in our
cohort ~ 7%), which we did not investigate. Imaging was
only available at a single time-point, and therefore it was
not possible to determine the influence of adiposity on
longitudinal imaging changes: this will be addressed in
future work. Furthermore, because this cohort is largely
cognitively normal, we cannot directly investigate associ-
ations with dementia prevalence at the present time.
In conclusion, we did not find consistent associations
to explain the reported relationship between obesity,
particularly in midlife, and late-life dementia risk, using
WMHV, β-amyloid status and brain volumes as indica-
tors of brain health. Indeed, being overweight or obese
in later midlife and early late life was associated with lar-
ger hippocampal volumes, and declining BMI in the 1–
2 years prior to scanning was associated with increased
risk of β-amyloid positivity, which may reflect the influ-
ence of neurodegeneration on body composition. Our
findings do not support interventions to tackle obesity
as an effective approach towards improving later-life
cerebral health, although these remain important for im-
proving other health outcomes including cardiovascular
and cancer risk. Declining BMI in later life may be a
marker of preclinical AD.
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